(#39) Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia

Abstract: OBJECTIVE: Combination olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatment was associated with significant reductions in acute healthcare resource utilization (HCRU) in a previous 6-month pre/post study. This study examined HCRU among patients with schizophrenia in the 12 months before and after OLZ/SAM initiation. METHODS: Administrative claims data from October 18, 2020, to December 31, 2023, from Komodoís Healthcare Map were analyzed retrospectively. Adults with schizophrenia and continuous enrollment ?12 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. Inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average numbers of inpatient days/patient were compared between baseline and follow-up. A secondary analysis was conducted for patients receiving OLZ/SAM treatment for the full 12-month follow-up period. RESULTS: Patients (n=1287; mean age: 39 years; female: 46%) were on average persistent for 196.6 days. Proportions of patients with ?1 all-cause, mental health (MH)-related, and schizophrenia-related IP admissions and ED visits significantly decreased between baseline and follow-up (all P